10 minute read
Oct. 2, 2023

A Next-Generation Mutant-Selective PI3Kα Allosteric Inhibitor with a Potentially Improved Safety Profile


mutant-selective, allosteric PI3Ka inhibitor Ph. I/II for breast cancer and other solid tumors from affinity selection mass spectrometry (ASMS) screen Cancer Discov., August 2023 Scorpion Therapeutics, Boston, MA


Molecules of the Month - August 2023

MOTY Nominees

Molecule of the Year